Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Pancreatic cancer (mmu05212)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Akt1
KLA  ATP  ATP+KLA
NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Araf
KLA  ATP  ATP+KLA
NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Arhgef6
KLA  ATP  ATP+KLA
AK028642 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732422I02 product:Rac/Cdc42 guanine exchange factor (GEF) 6, full insert sequence. [AK028642] KLA .55 .52 .59 .60 .69 .61 .60
ATP 1.29 1.30 .63 .50 .76 .62 .74
KLA/ATP .54 .52 .70 .61 .67 .50 .55
Arhgef6
KLA  ATP  ATP+KLA
NM_152801 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 (Arhgef6), mRNA [NM_152801] KLA .61 .64 .55 .52 .44 .37 .52
ATP 1.06 1.01 .97 1.02 .77 .58 .89
KLA/ATP .67 .65 .53 .58 .49 .43 .49
Bad
KLA  ATP  ATP+KLA
AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
BB229853
KLA  ATP  ATP+KLA
BB229853 gb|BB229853 RIKEN full-length enriched, 3 days neonate thymus Mus musculus cDNA clone A630023O21 3. [BB229853] KLA 6.32 5.94 6.13 6.41 7.39 12.33 6.08
ATP .39 .24 .33 .38 1.18 5.75 2.85
KLA/ATP 2.27 2.02 3.25 4.04 7.11 10.22 13.93
Bcl2l1
KLA  ATP  ATP+KLA
NM_009743 Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] KLA .99 1.02 1.10 1.16 1.27 .97 1.05
ATP 1.18 1.42 .81 1.26 1.51 .71 1.67
KLA/ATP 1.21 1.30 .66 1.15 1.31 1.17 1.59
BI646741
KLA  ATP  ATP+KLA
BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Braf
KLA  ATP  ATP+KLA
NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Brca2
KLA  ATP  ATP+KLA
NM_009765 breast cancer 2 (Brca2), transcript variant 2, mRNA [NM_009765] KLA .25 .23 .23 .26 .28 .29 .24
ATP .94 .94 1.19 .68 .36 .30 .28
KLA/ATP .23 .22 .33 .31 .30 .23 .19
Casp9
KLA  ATP  ATP+KLA
NM_015733 caspase 9 (Casp9), mRNA [NM_015733] KLA .31 .31 .40 .66 .89 1.19 .91
ATP .88 .77 .91 .59 .43 .75 .93
KLA/ATP .26 .26 .30 .28 .80 1.06 .97
Ccnd1
KLA  ATP  ATP+KLA
S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Cdc42
KLA  ATP  ATP+KLA
NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdk4
KLA  ATP  ATP+KLA
NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Cdk6
KLA  ATP  ATP+KLA
AK030810 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] KLA 1.05 .96 .67 .51 .48 .49 .45
ATP 1.02 .91 .78 .49 .50 .47 .44
KLA/ATP 1.01 .89 .65 .40 .36 .26 .49
Cdk6
KLA  ATP  ATP+KLA
NM_009873 cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] KLA 2.63 2.36 2.14 1.80 1.55 1.32 1.03
ATP 1.11 1.21 1.06 1.23 .94 1.30 2.08
KLA/ATP 2.58 2.69 2.24 2.25 1.38 .85 3.00
Cdkn2a
KLA  ATP  ATP+KLA
NM_009877 cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM_009877] KLA .95 .95 .86 .96 .91 .90 .75
ATP 1.00 .99 .95 .95 .97 .89 .77
KLA/ATP .95 .96 .92 .94 .90 .85 .76
Chuk
KLA  ATP  ATP+KLA
NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
E2f1
KLA  ATP  ATP+KLA
NM_007891 E2F transcription factor 1 (E2f1), mRNA [NM_007891] KLA .41 .44 .42 .41 .48 .77 .90
ATP 1.01 1.09 1.04 1.13 .83 .53 .84
KLA/ATP .44 .44 .52 .50 .49 .46 .85
E2f2
KLA  ATP  ATP+KLA
NM_177733 E2F transcription factor 2 (E2f2), mRNA [NM_177733] KLA .13 .13 .14 .20 .19 .19 .18
ATP 1.08 .92 1.01 .85 .65 .38 .38
KLA/ATP .13 .13 .21 .20 .32 .24 .26
E2f3
KLA  ATP  ATP+KLA
AK085296 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] KLA .98 .97 1.02 1.00 .99 .99 .99
ATP .97 1.06 1.03 .98 1.01 .99 1.00
KLA/ATP 1.12 1.14 1.03 .99 .96 .93 .96
E2f3
KLA  ATP  ATP+KLA
NM_010093 E2F transcription factor 3 (E2f3), mRNA [NM_010093] KLA 1.11 1.09 1.13 1.21 1.47 1.62 1.65
ATP .97 .98 1.08 1.15 1.45 1.73 1.80
KLA/ATP 1.21 1.13 1.07 1.20 1.45 1.56 1.62
Egf
KLA  ATP  ATP+KLA
NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Erbb2
KLA  ATP  ATP+KLA
NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Ikbkb
KLA  ATP  ATP+KLA
NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Jak1
KLA  ATP  ATP+KLA
AK029232 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] KLA 1.25 1.13 1.19 1.31 1.24 1.17 1.14
ATP 1.01 1.11 .96 1.38 1.06 1.26 1.05
KLA/ATP 1.19 1.29 1.27 1.59 1.18 1.38 1.24
Jak1
KLA  ATP  ATP+KLA
NM_146145 Janus kinase 1 (Jak1), mRNA [NM_146145] KLA 1.71 1.75 1.79 1.81 1.72 1.37 1.21
ATP 1.03 1.01 .75 1.04 1.32 1.90 1.14
KLA/ATP 1.84 1.73 1.49 2.07 2.01 1.83 1.68
Kras
KLA  ATP  ATP+KLA
NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Mapk1
KLA  ATP  ATP+KLA
NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk3
KLA  ATP  ATP+KLA
NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.21312
8
KLA  ATP  ATP+KLA
141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.23625
6
KLA  ATP  ATP+KLA
124487408 Unknown KLA .24 .22 .23 .24 .24 .30 .25
ATP .90 .95 1.24 .70 .34 .27 .28
KLA/ATP .21 .23 .31 .30 .30 .23 .18
Mm.25381
9
KLA  ATP  ATP+KLA
118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.27304
9
KLA  ATP  ATP+KLA
119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.30793
2
KLA  ATP  ATP+KLA
160333363 Unknown KLA .13 .12 .14 .16 .15 .18 .15
ATP .92 .94 1.12 .93 .58 .29 .31
KLA/ATP .11 .11 .18 .20 .28 .20 .19
Mm.4387
KLA  ATP  ATP+KLA
133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Nfkb1
KLA  ATP  ATP+KLA
BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Pik3ca
KLA  ATP  ATP+KLA
ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Pld1
KLA  ATP  ATP+KLA
NM_008875 phospholipase D1 (Pld1), mRNA [NM_008875] KLA .71 .73 .67 .73 .88 .96 1.25
ATP .99 .88 .73 .68 .45 1.23 1.12
KLA/ATP .70 .67 .58 .59 .48 .91 1.48
Rac1
KLA  ATP  ATP+KLA
NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Rad51
KLA  ATP  ATP+KLA
NM_011234 RAD51 homolog (S. cerevisiae) (Rad51), mRNA [NM_011234] KLA .44 .39 .39 .29 .16 .14 .12
ATP 1.13 .90 .69 .63 .38 .25 .09
KLA/ATP .47 .38 .35 .23 .18 .10 .06
Raf1
KLA  ATP  ATP+KLA
AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rala
KLA  ATP  ATP+KLA
NM_019491 v-ral simian leukemia viral oncogene homolog A (ras related) (Rala), mRNA [NM_019491] KLA 1.02 1.05 1.01 1.18 1.31 1.22 2.24
ATP 1.06 1.07 1.08 1.30 1.44 1.43 1.34
KLA/ATP 1.04 1.08 .98 1.07 1.28 1.34 2.01
Ralb
KLA  ATP  ATP+KLA
NM_022327 v-ral simian leukemia viral oncogene homolog B (ras related) (Ralb), mRNA [NM_022327] KLA 1.10 .98 .89 1.12 1.14 1.47 1.04
ATP .89 .82 .88 .72 .81 1.28 .97
KLA/ATP .84 .85 .85 .73 1.00 1.36 1.20
Ralbp1
KLA  ATP  ATP+KLA
NM_009067 ralA binding protein 1 (Ralbp1), mRNA [NM_009067] KLA .71 .64 .67 .63 .67 .63 .77
ATP 1.09 1.05 .78 .73 .68 .72 .78
KLA/ATP .79 .73 .55 .50 .54 .52 .61
Ralgds
KLA  ATP  ATP+KLA
NM_009058 ral guanine nucleotide dissociation stimulator (Ralgds), mRNA [NM_009058] KLA 4.29 4.39 3.93 3.90 3.91 3.29 3.29
ATP .91 .92 1.56 3.84 7.41 6.08 2.29
KLA/ATP 3.37 4.34 5.23 7.26 10.22 6.72 6.05
Rb1
KLA  ATP  ATP+KLA
NM_009029 retinoblastoma 1 (Rb1), mRNA [NM_009029] KLA .67 .60 .55 .51 .46 .75 .79
ATP 1.04 1.01 1.12 .86 .59 .43 .76
KLA/ATP .64 .59 .58 .46 .36 .30 .65
Rela
KLA  ATP  ATP+KLA
NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Smad2
KLA  ATP  ATP+KLA
NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smad3
KLA  ATP  ATP+KLA
NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad4
KLA  ATP  ATP+KLA
NM_008540 MAD homolog 4 (Drosophila) (Smad4), mRNA [NM_008540] KLA 1.11 1.11 1.13 1.09 1.02 .98 1.08
ATP 1.00 1.04 .92 .76 1.67 1.44 .92
KLA/ATP 1.09 1.01 .87 .89 1.64 1.43 .99
Stat1
KLA  ATP  ATP+KLA
NM_009283 signal transducer and activator of transcription 1 (Stat1), mRNA [NM_009283] KLA 2.90 2.72 3.00 3.64 4.58 6.51 5.58
ATP 1.01 .92 .89 .72 .51 2.22 3.07
KLA/ATP 2.73 2.65 2.34 1.95 1.99 4.70 8.66
Stat3
KLA  ATP  ATP+KLA
NM_213659 signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA [NM_213659] KLA 4.36 4.42 4.67 6.02 4.95 3.45 1.46
ATP 1.01 .97 1.07 1.17 2.47 4.04 1.47
KLA/ATP 4.02 4.57 6.65 6.51 7.06 7.39 3.61
Tgfa
KLA  ATP  ATP+KLA
NM_031199 transforming growth factor alpha (Tgfa), mRNA [NM_031199] KLA 1.01 .99 1.00 1.03 1.01 1.04 1.04
ATP 1.01 1.04 1.02 1.02 1.02 1.01 1.05
KLA/ATP 1.01 1.02 1.02 1.02 1.02 1.06 1.02
Tgfb1
KLA  ATP  ATP+KLA
NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Trp53
KLA  ATP  ATP+KLA
NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Vegfa
KLA  ATP  ATP+KLA
NM_001025250 vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] KLA .49 .48 .46 .46 .39 .64 1.18
ATP 1.05 1.37 3.82 10.55 12.51 24.20 7.85
KLA/ATP .48 .59 1.45 7.42 19.75 27.42 22.35
Vegfa
KLA  ATP  ATP+KLA
NM_001025257 vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] KLA .72 .71 .66 .70 .65 .80 1.22
ATP 1.01 1.21 3.24 11.12 11.09 18.59 5.43
KLA/ATP .68 .71 1.47 5.94 15.06 20.32 17.31